{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:31:01Z","timestamp":1783373461178,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaip.2026.01.045","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:06:52Z","timestamp":1771315612000},"page":"1515-1521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic Manifestations of STAT1 Gain-of-Function Variants"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3493-6925","authenticated-orcid":false,"given":"Wesam","family":"Aleyadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanrun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana A.","family":"Pirzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"Fathma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna R.E.","family":"Bergerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail S.","family":"Lionakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.01.045_bib1","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity","volume":"42","author":"Bousfiha","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2026.01.045_bib3","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaip.2026.01.045_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029248","article-title":"STAT1 hyperphosphorylation and defective IL12R\/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis","volume":"6","author":"Smeekens","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2026.01.045_bib5","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3389\/fimmu.2019.01433","article-title":"STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation","volume":"10","author":"Zimmerman","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","article-title":"Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation","volume":"38","author":"Bloomfield","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10875-022-01351-0","article-title":"Three adult cases of STAT1 gain-of-function with chronic mucocutaneous candidiasis treated with JAK inhibitors","volume":"43","author":"Borgstr\u00f6m","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10875-024-01684-y","article-title":"Patients with STAT1 gain-of-function mutations display increased apoptosis which is reversed by the JAK inhibitor ruxolitinib","volume":"44","author":"Dotta","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib11","article-title":"Clinical relevance of gain- and loss-of-function germline mutations in STAT1: a systematic review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/ACI.0000000000001039","article-title":"STAT1 and STAT3 gain of function: clinically heterogenous immune regulatory disorders","volume":"24","author":"Olbrich","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","article-title":"Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome","volume":"131","author":"Uzel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2018.11.033","article-title":"STAT1 gain-of-function compromises skin host defense in the context of IFN-gamma signaling","volume":"143","author":"Niehues","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5731","article-title":"Aberrant type 1 immunity drives susceptibility to mucosal fungal infections","volume":"371","author":"Break","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jaip.2026.01.045_bib16","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3389\/fimmu.2018.03047","article-title":"IRF and STAT transcription factors - from basic biology to roles in infection, protective immunity, and primary immunodeficiencies","volume":"9","author":"Mogensen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade7028","article-title":"Dysregulated IFN-gamma signals promote autoimmunity in STAT1 gain-of-function syndrome","volume":"15","author":"Largent","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2026.01.045_bib18","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1084\/jem.20161427","article-title":"PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients","volume":"214","author":"Zhang","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaip.2026.01.045_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10875-022-01257-x","article-title":"Impact of JAK inhibitors in pediatric patients with STAT1 gain of function (GOF) mutations-10 children and review of the literature","volume":"42","author":"Deya-Martinez","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib20","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2026.01.045_bib21","article-title":"Gain-of-function mutations in STAT1: a recently defined cause for chronic mucocutaneous candidiasis disease mimicking combined immunodeficiencies","volume":"2017","author":"Eren Akarcan","year":"2017","journal-title":"Case Rep Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10875-012-9744-6","article-title":"Autosomal-dominant chronic mucocutaneous candidiasis with STAT1-mutation can be complicated with chronic active hepatitis and hypothyroidism","volume":"32","author":"Hori","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib23","article-title":"Autosomal dominant chronic mucocutaneous candidiasis with STAT1 mutation can be associated with chronic active hepatitis: a case report","volume":"10","author":"Liu","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaip.2026.01.045_bib24","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/hep.32539","article-title":"Tip of the iceberg: a comprehensive review of liver disease in Inborn errors of immunity","volume":"76","author":"Sharma","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jaip.2026.01.045_bib25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10875-013-9873-6","article-title":"Nodular regenerative hyperplasia in common variable immunodeficiency","volume":"33","author":"Fuss","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2007.08.011","article-title":"Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities","volume":"48","author":"Malamut","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaip.2026.01.045_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.152833","article-title":"Nodular regenerative hyperplasia - an under-recognized vascular disorder of liver","volume":"216","author":"Bakshi","year":"2020","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jaip.2026.01.045_bib28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/his.14083","article-title":"Aberrant von Willebrand factor expression of sinusoidal endothelial cells and quiescence of hepatic stellate cells in nodular regenerative hyperplasia and obliterative portal venopathy","volume":"76","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.jaip.2026.01.045_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.20024","article-title":"Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders","volume":"75","author":"Al-Mukhaizeem","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2026.01.045_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12013-012-9379-5","article-title":"Clinical analysis of 15 cases of liver nodular regenerative hyperplasia","volume":"64","author":"Guo","year":"2012","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.jaip.2026.01.045_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.32367","article-title":"Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: a case-control study","volume":"76","author":"Valainathan","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jaip.2026.01.045_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88782","article-title":"Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"1","author":"Ferre","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaip.2026.01.045_bib33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/hep.31421","article-title":"APECED-associated hepatitis: clinical, biochemical, histological and treatment data from a large, predominantly American cohort","volume":"73","author":"Chascsa","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jaip.2026.01.045_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.723532","article-title":"Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"9","author":"Ferre","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaip.2026.01.045_bib35","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1056\/NEJMoa2312665","article-title":"The role of interferon-gamma in autoimmune polyendocrine syndrome type 1","volume":"390","author":"Oikonomou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.045_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.alit.2021.07.007","article-title":"Hyper-IgE syndrome, 2021 update","volume":"70","author":"Minegishi","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2026.01.045_bib37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1084\/jem.20082767","article-title":"Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome","volume":"206","author":"Minegishi","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaip.2026.01.045_bib38","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41590-019-0377-2","article-title":"CARD9+ microglia promote antifungal immunity via IL-1beta- and CXCL1-mediated neutrophil recruitment","volume":"20","author":"Drummond","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib40","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa0810719","article-title":"A homozygous CARD9 mutation in a family with susceptibility to fungal infections","volume":"361","author":"Glocker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.045_bib41","article-title":"CARD9 deficiency aggravated nonalcoholic steatohepatitis in mice through increasing inflammatory response","volume":"1870","author":"Liu","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jaip.2026.01.045_bib42","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3389\/fimmu.2018.01836","article-title":"Human CARD9: a critical molecule of fungal immune surveillance","volume":"9","author":"Drummond","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1056\/NEJMc2311867","article-title":"JAK inhibition in STAT1 gain-of-function-mediated treatment-resistant autoimmune hepatitis","volume":"390","author":"Hadzic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.01.045_bib44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jaip.2026.01.045_bib45","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","article-title":"JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID\/EBMT-IEWP retrospective study","volume":"153","author":"Fischer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib47","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10875-013-9947-5","article-title":"A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation","volume":"33","author":"Aldave","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10875-018-0575-y","article-title":"Hematopoietic stem cell transplantation in patients with heterozygous STAT1 gain-of-function mutation","volume":"39","author":"Kiykim","year":"2019","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib49","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib50","doi-asserted-by":"crossref","DOI":"10.70962\/jhi.20250027","article-title":"Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging","volume":"1","author":"Buddingh","year":"2025","journal-title":"J Hum Immun"},{"key":"10.1016\/j.jaip.2026.01.045_bib51","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaci.2023.05.016","article-title":"Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations","volume":"152","author":"Kunvarjee","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.01.045_bib52","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/cid\/civ1220","article-title":"Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature","volume":"62","author":"Zerbe","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:56:27Z","timestamp":1783331787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2213219826001443"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.045","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Manifestations of STAT1 Gain-of-Function Variants","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}